Agios Pharmaceuticals Inc (NASDAQ:AGIO) Shorts Decreased by 9.79% After Short Covering

February 21, 2018 - By Henry Gaston

 Agios Pharmaceuticals Inc (NASDAQ:AGIO) Shorts Decreased by 9.79% After Short Covering

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.83, from 2.04 in 2017Q2. It turned negative, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported.
Us Bancorporation De has 130 shares. Valley National Advisers has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Commercial Bank Of Mellon Corporation stated it has 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Loomis Sayles & Co L P stated it has 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Cap International holds 3.14 million shares or 0.25% of its portfolio. Alliancebernstein Limited Partnership reported 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Ontario – Canada-based Bankshares Of Montreal Can has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Voya Investment Mngmt accumulated 15,557 shares. Tarbox Family Office Inc reported 16 shares. Tiaa Cref Invest Management has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 112,813 shares. Federated Pa has 27,876 shares. Balyasny Asset Mgmt Limited Company holds 0.25% or 966,152 shares. The California-based Cap Guardian Communication has invested 0.85% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Goldman Sachs Gru reported 0.02% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Public Employees Retirement Association Of Colorado holds 6,505 shares or 0% of its portfolio.

Since August 22, 2017, it had 0 insider buys, and 22 selling transactions for $24.95 million activity. Cantley Lewis Clayton Jr. sold $227,400 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, August 22. On Wednesday, January 24 the insider Schenkein David P sold $1,600. Biller Scott had sold 10,470 shares worth $732,900 on Wednesday, October 4. Hoerter Steven L. also sold $1.87M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, January 23. Another trade for 2,150 shares valued at $161,250 was sold by Alenson Carman.

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) registered a decrease of 9.79% in short interest. AGIO’s total short interest was 6.07 million shares in February as published by FINRA. Its down 9.79% from 6.72 million shares, reported previously. With 1.21 million shares average volume, it will take short sellers 5 days to cover their AGIO’s short positions. The short interest to Agios Pharmaceuticals Inc’s float is 14.12%.

The stock increased 2.04% or $1.58 during the last trading session, reaching $79.11. About 146,407 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 21, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.54 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 44 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by SunTrust with “Buy” on Tuesday, October 3. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Hold” rating given on Wednesday, August 5 by Roth Capital. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Suntrust Robinson on Wednesday, May 18. The stock has “Buy” rating by RBC Capital Markets on Wednesday, November 1. Oppenheimer maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, August 1 with “Buy” rating. The company was upgraded on Monday, June 13 by Canaccord Genuity. The stock has “Buy” rating by Oppenheimer on Sunday, June 11. TH Capital maintained the shares of AGIO in report on Monday, November 9 with “Neutral” rating. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Needham on Monday, October 24. On Thursday, June 1 the stock rating was maintained by Oppenheimer with “Buy”.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Streetinsider.com which released: “Agios Pharma (AGIO) Says FDA Accepted NDA and Granted Priority Review for …” on February 15, 2018, also Nasdaq.com with their article: “Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y” published on February 15, 2018, Zacks.com published: “FDA Grants Agios’ (AGIO) Leukemia Candidate Priority Review” on February 16, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Globenewswire.com and their article: “Agios Announces Closing of Public Offering and Full Exercise of Option to …” published on January 23, 2018 as well as Nasdaq.com‘s news article titled: “Agios Pharmaceuticals (AGIO) Q4 Earnings: What’s in Store?” with publication date: February 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.